Toshiji Shitara, Akira Shimada, Ryoji Hanada, Tadashi Matsunaga, Keisei Kawa, Hideo Mugishima, Tohru Sugimoto, Jun-ichi Mimaya, Atsushi Manabe, Masahito Tsurusawa, Yoshiaki Tsuchida
Pediatric hematology and oncology 23(2) 103-10 2006年3月 査読有り
Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.